HRP20120166T1 - Supstituirane n-bipirolidinuree i njihova upotreba u terapiji - Google Patents
Supstituirane n-bipirolidinuree i njihova upotreba u terapiji Download PDFInfo
- Publication number
- HRP20120166T1 HRP20120166T1 HR20120166T HRP20120166T HRP20120166T1 HR P20120166 T1 HRP20120166 T1 HR P20120166T1 HR 20120166 T HR20120166 T HR 20120166T HR P20120166 T HRP20120166 T HR P20120166T HR P20120166 T1 HRP20120166 T1 HR P20120166T1
- Authority
- HR
- Croatia
- Prior art keywords
- methyl
- phenyl
- bipyrrolidinyl
- amide
- carboxylic acid
- Prior art date
Links
- 235000013877 carbamide Nutrition 0.000 title abstract 3
- 230000001225 therapeutic effect Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract 8
- 201000010099 disease Diseases 0.000 claims abstract 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 13
- -1 thiophen-2-ylmethyl Chemical group 0.000 claims 8
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims 6
- 239000001257 hydrogen Substances 0.000 claims 6
- 229910052739 hydrogen Inorganic materials 0.000 claims 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 5
- 150000001408 amides Chemical class 0.000 claims 5
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims 4
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 3
- 239000004202 carbamide Substances 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 206010012289 Dementia Diseases 0.000 claims 2
- 206010041349 Somnolence Diseases 0.000 claims 2
- 208000010877 cognitive disease Diseases 0.000 claims 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 2
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- STUHQDIOZQUPGP-UHFFFAOYSA-N morpholin-4-ium-4-carboxylate Chemical compound OC(=O)N1CCOCC1 STUHQDIOZQUPGP-UHFFFAOYSA-N 0.000 claims 2
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
- ZPPXWZDJDIOJFP-UHFFFAOYSA-N 1,3-dihydroisoindole-2-carboxylic acid Chemical compound C1=CC=C2CN(C(=O)O)CC2=C1 ZPPXWZDJDIOJFP-UHFFFAOYSA-N 0.000 claims 1
- TXYHNJMNQMYNTO-UHFFFAOYSA-N 1-(3,5-dichlorophenyl)-3-[2-methyl-4-[3-(2-methylpyrrolidin-1-yl)pyrrolidin-1-yl]phenyl]urea Chemical compound CC1CCCN1C1CN(C=2C=C(C)C(NC(=O)NC=3C=C(Cl)C=C(Cl)C=3)=CC=2)CC1 TXYHNJMNQMYNTO-UHFFFAOYSA-N 0.000 claims 1
- RHEVIGLLTLURAQ-UHFFFAOYSA-N 1-(3,5-dichlorophenyl)-3-[3-methyl-4-[3-(2-methylpyrrolidin-1-yl)pyrrolidin-1-yl]phenyl]urea Chemical compound CC1CCCN1C1CN(C=2C(=CC(NC(=O)NC=3C=C(Cl)C=C(Cl)C=3)=CC=2)C)CC1 RHEVIGLLTLURAQ-UHFFFAOYSA-N 0.000 claims 1
- GURFDWVYTCEBLB-UHFFFAOYSA-N 1-(3,5-dichlorophenyl)-3-[4-[3-(2-methylpyrrolidin-1-yl)pyrrolidin-1-yl]phenyl]urea Chemical compound CC1CCCN1C1CN(C=2C=CC(NC(=O)NC=3C=C(Cl)C=C(Cl)C=3)=CC=2)CC1 GURFDWVYTCEBLB-UHFFFAOYSA-N 0.000 claims 1
- UCSCBDCRYZONHX-UHFFFAOYSA-N 1-(3-cyanophenyl)-3-[3-methyl-4-[3-(2-methylpyrrolidin-1-yl)pyrrolidin-1-yl]phenyl]urea Chemical compound CC1CCCN1C1CN(C=2C(=CC(NC(=O)NC=3C=C(C=CC=3)C#N)=CC=2)C)CC1 UCSCBDCRYZONHX-UHFFFAOYSA-N 0.000 claims 1
- JEMKFSIFMPGUKZ-UHFFFAOYSA-N 1-(3-cyanophenyl)-3-[4-[3-(2-methylpyrrolidin-1-yl)pyrrolidin-1-yl]phenyl]urea Chemical compound CC1CCCN1C1CN(C=2C=CC(NC(=O)NC=3C=C(C=CC=3)C#N)=CC=2)CC1 JEMKFSIFMPGUKZ-UHFFFAOYSA-N 0.000 claims 1
- KBIMBEHOSLKBMG-UHFFFAOYSA-N 1-[(3,5-dichlorophenyl)methyl]-3-[3-methyl-4-[3-(2-methylpyrrolidin-1-yl)pyrrolidin-1-yl]phenyl]urea Chemical compound CC1CCCN1C1CN(C=2C(=CC(NC(=O)NCC=3C=C(Cl)C=C(Cl)C=3)=CC=2)C)CC1 KBIMBEHOSLKBMG-UHFFFAOYSA-N 0.000 claims 1
- ZSUUYMKBUDJXPU-UHFFFAOYSA-N 1-[(3,5-dichlorophenyl)methyl]-3-[4-[3-(2-methylpyrrolidin-1-yl)pyrrolidin-1-yl]-2-(trifluoromethyl)phenyl]urea Chemical compound CC1CCCN1C1CN(C=2C=C(C(NC(=O)NCC=3C=C(Cl)C=C(Cl)C=3)=CC=2)C(F)(F)F)CC1 ZSUUYMKBUDJXPU-UHFFFAOYSA-N 0.000 claims 1
- CCDWSMJPLNHEDZ-UHFFFAOYSA-N 1-[3-methyl-4-[3-(2-methylpyrrolidin-1-yl)pyrrolidin-1-yl]phenyl]-3-(thiophen-2-ylmethyl)urea Chemical compound CC1CCCN1C1CN(C=2C(=CC(NC(=O)NCC=3SC=CC=3)=CC=2)C)CC1 CCDWSMJPLNHEDZ-UHFFFAOYSA-N 0.000 claims 1
- MWATVQYCLGPJBC-UHFFFAOYSA-N 1-[4-[3-(2-methylpyrrolidin-1-yl)pyrrolidin-1-yl]phenyl]-3-(thiophen-2-ylmethyl)urea Chemical compound CC1CCCN1C1CN(C=2C=CC(NC(=O)NCC=3SC=CC=3)=CC=2)CC1 MWATVQYCLGPJBC-UHFFFAOYSA-N 0.000 claims 1
- CTQMYZRBBXTDJI-UHFFFAOYSA-N 1-cyclohexyl-3-[2-methyl-4-[3-(2-methylpyrrolidin-1-yl)pyrrolidin-1-yl]phenyl]urea Chemical compound CC1CCCN1C1CN(C=2C=C(C)C(NC(=O)NC3CCCCC3)=CC=2)CC1 CTQMYZRBBXTDJI-UHFFFAOYSA-N 0.000 claims 1
- VMHFMQVWQIGSIQ-UHFFFAOYSA-N 1-cyclohexyl-3-[3-methyl-4-[3-(2-methylpyrrolidin-1-yl)pyrrolidin-1-yl]phenyl]urea Chemical compound CC1CCCN1C1CN(C=2C(=CC(NC(=O)NC3CCCCC3)=CC=2)C)CC1 VMHFMQVWQIGSIQ-UHFFFAOYSA-N 0.000 claims 1
- ZFXGNBOXQNGCFE-UHFFFAOYSA-N 1-cyclohexyl-3-[4-[3-(2-methylpyrrolidin-1-yl)pyrrolidin-1-yl]phenyl]urea Chemical compound CC1CCCN1C1CN(C=2C=CC(NC(=O)NC3CCCCC3)=CC=2)CC1 ZFXGNBOXQNGCFE-UHFFFAOYSA-N 0.000 claims 1
- QVEYYVHLQBRQNF-UHFFFAOYSA-N 4-acetyl-n-[3-methyl-4-[3-(2-methylpyrrolidin-1-yl)pyrrolidin-1-yl]phenyl]piperazine-1-carboxamide Chemical compound CC1CCCN1C1CN(C=2C(=CC(NC(=O)N3CCN(CC3)C(C)=O)=CC=2)C)CC1 QVEYYVHLQBRQNF-UHFFFAOYSA-N 0.000 claims 1
- BCCVUKGKQRRJOM-UHFFFAOYSA-N 4-acetyl-n-[4-[3-(2-methylpyrrolidin-1-yl)pyrrolidin-1-yl]phenyl]piperazine-1-carboxamide Chemical compound CC1CCCN1C1CN(C=2C=CC(NC(=O)N3CCN(CC3)C(C)=O)=CC=2)CC1 BCCVUKGKQRRJOM-UHFFFAOYSA-N 0.000 claims 1
- NXMHCJSGJBPRQM-UHFFFAOYSA-N 4-ethylpiperazine-1-carboxylic acid Chemical compound CCN1CCN(C(O)=O)CC1 NXMHCJSGJBPRQM-UHFFFAOYSA-N 0.000 claims 1
- PHOGKWBKNQASCX-UHFFFAOYSA-N 4-methyl-n-[2-methyl-4-[3-(2-methylpyrrolidin-1-yl)pyrrolidin-1-yl]phenyl]piperazine-1-carboxamide Chemical compound CC1CCCN1C1CN(C=2C=C(C)C(NC(=O)N3CCN(C)CC3)=CC=2)CC1 PHOGKWBKNQASCX-UHFFFAOYSA-N 0.000 claims 1
- XIGBTIXFXCZLOP-UHFFFAOYSA-N 4-methyl-n-[3-methyl-4-[3-(2-methylpyrrolidin-1-yl)pyrrolidin-1-yl]phenyl]piperazine-1-carboxamide Chemical compound CC1CCCN1C1CN(C=2C(=CC(NC(=O)N3CCN(C)CC3)=CC=2)C)CC1 XIGBTIXFXCZLOP-UHFFFAOYSA-N 0.000 claims 1
- WGDBSIUKEGGNAD-UHFFFAOYSA-N 4-methyl-n-[4-[3-(2-methylpyrrolidin-1-yl)pyrrolidin-1-yl]phenyl]piperazine-1-carboxamide Chemical compound CC1CCCN1C1CN(C=2C=CC(NC(=O)N3CCN(C)CC3)=CC=2)CC1 WGDBSIUKEGGNAD-UHFFFAOYSA-N 0.000 claims 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 1
- 208000028698 Cognitive impairment Diseases 0.000 claims 1
- 125000003047 N-acetyl group Chemical group 0.000 claims 1
- 208000005793 Restless legs syndrome Diseases 0.000 claims 1
- 208000032140 Sleepiness Diseases 0.000 claims 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 1
- 239000000460 chlorine Substances 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- FZUWGYJOMCWJQG-UHFFFAOYSA-N n-[2-methyl-4-[3-(2-methylpyrrolidin-1-yl)pyrrolidin-1-yl]phenyl]-1,3-dihydroisoindole-2-carboxamide Chemical compound CC1CCCN1C1CN(C=2C=C(C)C(NC(=O)N3CC4=CC=CC=C4C3)=CC=2)CC1 FZUWGYJOMCWJQG-UHFFFAOYSA-N 0.000 claims 1
- CDFWMRLTDLRZNL-UHFFFAOYSA-N n-[3-methyl-4-[3-(2-methylpyrrolidin-1-yl)pyrrolidin-1-yl]phenyl]piperidine-1-carboxamide Chemical compound CC1CCCN1C1CN(C=2C(=CC(NC(=O)N3CCCCC3)=CC=2)C)CC1 CDFWMRLTDLRZNL-UHFFFAOYSA-N 0.000 claims 1
- HBWGNGFOCQPSDC-UHFFFAOYSA-N n-[4-[3-(2-methylpyrrolidin-1-yl)pyrrolidin-1-yl]phenyl]-1,3-dihydroisoindole-2-carboxamide Chemical compound CC1CCCN1C1CN(C=2C=CC(NC(=O)N3CC4=CC=CC=C4C3)=CC=2)CC1 HBWGNGFOCQPSDC-UHFFFAOYSA-N 0.000 claims 1
- OSBYOAIKJPMFDA-UHFFFAOYSA-N n-[4-[3-(2-methylpyrrolidin-1-yl)pyrrolidin-1-yl]phenyl]-4-phenylpiperazine-1-carboxamide Chemical compound CC1CCCN1C1CN(C=2C=CC(NC(=O)N3CCN(CC3)C=3C=CC=CC=3)=CC=2)CC1 OSBYOAIKJPMFDA-UHFFFAOYSA-N 0.000 claims 1
- PYUCVLVRHYGSER-UHFFFAOYSA-N n-[4-[3-(2-methylpyrrolidin-1-yl)pyrrolidin-1-yl]phenyl]piperidine-1-carboxamide Chemical compound CC1CCCN1C1CN(C=2C=CC(NC(=O)N3CCCCC3)=CC=2)CC1 PYUCVLVRHYGSER-UHFFFAOYSA-N 0.000 claims 1
- 201000003631 narcolepsy Diseases 0.000 claims 1
- 208000001797 obstructive sleep apnea Diseases 0.000 claims 1
- 230000000737 periodic effect Effects 0.000 claims 1
- 230000033764 rhythmic process Effects 0.000 claims 1
- 208000019116 sleep disease Diseases 0.000 claims 1
- 208000020685 sleep-wake disease Diseases 0.000 claims 1
- 230000037321 sleepiness Effects 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
- 102000004384 Histamine H3 receptors Human genes 0.000 abstract 2
- 108090000981 Histamine H3 receptors Proteins 0.000 abstract 2
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008177 pharmaceutical agent Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Psychology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Transplantation (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Toxicology (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US98060607P | 2007-10-17 | 2007-10-17 | |
PCT/US2008/079763 WO2009052068A1 (en) | 2007-10-17 | 2008-10-14 | Substituted n-phenyl-bipyrrolidine ureas and therapeutic use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20120166T1 true HRP20120166T1 (hr) | 2012-03-31 |
Family
ID=40248052
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HR20120166T HRP20120166T1 (hr) | 2007-10-17 | 2012-02-20 | Supstituirane n-bipirolidinuree i njihova upotreba u terapiji |
Country Status (25)
Country | Link |
---|---|
US (1) | US8222290B2 (pt) |
EP (1) | EP2215058B1 (pt) |
JP (1) | JP5380455B2 (pt) |
KR (1) | KR20100082349A (pt) |
CN (1) | CN101903341B (pt) |
AT (1) | ATE534625T1 (pt) |
AU (1) | AU2008312641A1 (pt) |
CA (1) | CA2702933C (pt) |
CY (1) | CY1112391T1 (pt) |
DK (1) | DK2215058T3 (pt) |
ES (1) | ES2378011T3 (pt) |
HK (1) | HK1146056A1 (pt) |
HR (1) | HRP20120166T1 (pt) |
IL (1) | IL205002A0 (pt) |
MA (1) | MA31889B1 (pt) |
MX (1) | MX2010003948A (pt) |
MY (1) | MY148807A (pt) |
NZ (1) | NZ584692A (pt) |
PL (1) | PL2215058T3 (pt) |
PT (1) | PT2215058E (pt) |
RS (1) | RS52221B (pt) |
RU (1) | RU2478094C2 (pt) |
SI (1) | SI2215058T1 (pt) |
WO (1) | WO2009052068A1 (pt) |
ZA (1) | ZA201002114B (pt) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT2205558E (pt) | 2007-10-17 | 2012-11-02 | Sanofi Sa | Amidas de n-fenil-pirrolidinilmetilpirrolidina substituídas e sua utilização terapêutica como moduladores do receptor h3 da histamina |
MX2010003949A (es) | 2007-10-17 | 2010-04-30 | Sanofi Aventis | N-fenil-bipirrolidina carboxamidas sustituidas y uso terapeutico de las mismas. |
RU2477719C2 (ru) * | 2007-10-17 | 2013-03-20 | Санофи-Авентис | Замещенные n-фенилбипирролидинкарбоксамиды и их терапевтическое применение |
US10412788B2 (en) | 2008-06-13 | 2019-09-10 | Lg Chem, Ltd. | Heating element and manufacturing method thereof |
JP5021842B2 (ja) * | 2008-06-13 | 2012-09-12 | エルジー・ケム・リミテッド | 発熱体およびその製造方法 |
KR20090129927A (ko) | 2008-06-13 | 2009-12-17 | 주식회사 엘지화학 | 발열체 및 이의 제조방법 |
TW201206444A (en) | 2010-05-11 | 2012-02-16 | Sanofi Aventis | Substituted N-heteroaryl tetrahydro-isoquinoline derivatives, preparation and therapeutic use thereof |
WO2011143148A1 (en) | 2010-05-11 | 2011-11-17 | Sanofi | Substituted n-heteroaryl spirolactam bipyrrolidines, preparation and therapeutic use thereof |
EP2569296A1 (en) * | 2010-05-11 | 2013-03-20 | Sanofi | Substituted n-phenyl spirolactam bipyrrolidines, preparation and therapeutic use thereof |
TW201206889A (en) | 2010-05-11 | 2012-02-16 | Sanofi Aventis | Substituted N-alkyl and N-acyl tetrahydro-isoquinoline derivatives, preparation and therapeutic use thereof |
JP5968307B2 (ja) | 2010-05-11 | 2016-08-10 | サノフイ | 置換フェニルシクロアルキルピロリジン(ピペリジン)スピロラクタム類及びアミド類、それらの製造及び治療的使用 |
AR081383A1 (es) | 2010-05-11 | 2012-08-29 | Sanofi Aventis | N-heteroaril bipirrolidin carboxamidas sustituidas, composiciones farmaceuticas que las contienen y uso de las mismas para el tratamiento de enfermedades del sistema nervioso central. |
JP2013529198A (ja) * | 2010-05-11 | 2013-07-18 | サノフイ | 置換されたn−ヘテロシクロアルキルビピロリジニルフェニルアミド誘導体、その製造及び治療上の使用 |
MX2013005454A (es) | 2010-11-15 | 2013-06-24 | Abbvie Inc | Inhibidores de nampt y rock. |
CN103443093B (zh) * | 2011-02-23 | 2015-02-25 | 苏文生命科学有限公司 | 作为组胺h3受体配体的化合物 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PE20020507A1 (es) * | 2000-10-17 | 2002-06-25 | Schering Corp | Compuestos no-imidazoles como antagonistas del receptor histamina h3 |
AU2003287206A1 (en) * | 2002-10-23 | 2004-05-13 | Janssen Pharmaceutica, N.V. | Phenylpiperidines and phenylpyrrolidines as histamine h3 receptor modulators |
DE10306250A1 (de) * | 2003-02-14 | 2004-09-09 | Aventis Pharma Deutschland Gmbh | Substituierte N-Arylheterozyklen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
US7223788B2 (en) * | 2003-02-14 | 2007-05-29 | Sanofi-Aventis Deutschland Gmbh | Substituted N-aryl heterocycles, process for their preparation and their use as medicaments |
US7951826B2 (en) | 2005-03-17 | 2011-05-31 | Eli Lilly And Company | Pyrrolidine derivatives as histamine H3 receptor antagonists |
EP1868991B1 (en) * | 2005-04-01 | 2014-07-30 | Eli Lilly And Company | Histamine h3 receptor agents, preparation and therapeutic uses |
CN101263112B (zh) * | 2005-07-01 | 2012-10-10 | 伊莱利利公司 | 组胺h3受体药物、其制备和治疗用途 |
AU2006308167A1 (en) * | 2005-10-27 | 2007-05-03 | Ucb Pharma, S.A. | Compounds comprising a lactam or a lactam derivative moiety, processes for making them, and their uses |
PT2205558E (pt) | 2007-10-17 | 2012-11-02 | Sanofi Sa | Amidas de n-fenil-pirrolidinilmetilpirrolidina substituídas e sua utilização terapêutica como moduladores do receptor h3 da histamina |
MX2010003949A (es) | 2007-10-17 | 2010-04-30 | Sanofi Aventis | N-fenil-bipirrolidina carboxamidas sustituidas y uso terapeutico de las mismas. |
RU2477719C2 (ru) | 2007-10-17 | 2013-03-20 | Санофи-Авентис | Замещенные n-фенилбипирролидинкарбоксамиды и их терапевтическое применение |
-
2008
- 2008-10-14 EP EP08838702A patent/EP2215058B1/en active Active
- 2008-10-14 CA CA2702933A patent/CA2702933C/en not_active Expired - Fee Related
- 2008-10-14 NZ NZ584692A patent/NZ584692A/en not_active IP Right Cessation
- 2008-10-14 JP JP2010530054A patent/JP5380455B2/ja not_active Expired - Fee Related
- 2008-10-14 AT AT08838702T patent/ATE534625T1/de active
- 2008-10-14 RU RU2010119554/04A patent/RU2478094C2/ru not_active IP Right Cessation
- 2008-10-14 WO PCT/US2008/079763 patent/WO2009052068A1/en active Application Filing
- 2008-10-14 CN CN2008801212096A patent/CN101903341B/zh not_active Expired - Fee Related
- 2008-10-14 SI SI200830552T patent/SI2215058T1/sl unknown
- 2008-10-14 KR KR1020107010481A patent/KR20100082349A/ko not_active Application Discontinuation
- 2008-10-14 DK DK08838702.2T patent/DK2215058T3/da active
- 2008-10-14 PT PT08838702T patent/PT2215058E/pt unknown
- 2008-10-14 ES ES08838702T patent/ES2378011T3/es active Active
- 2008-10-14 RS RS20120067A patent/RS52221B/en unknown
- 2008-10-14 PL PL08838702T patent/PL2215058T3/pl unknown
- 2008-10-14 MY MYPI2010001300A patent/MY148807A/en unknown
- 2008-10-14 AU AU2008312641A patent/AU2008312641A1/en not_active Abandoned
- 2008-10-14 MX MX2010003948A patent/MX2010003948A/es active IP Right Grant
-
2010
- 2010-03-15 US US12/724,045 patent/US8222290B2/en active Active
- 2010-03-25 ZA ZA2010/02114A patent/ZA201002114B/en unknown
- 2010-04-11 IL IL205002A patent/IL205002A0/en unknown
- 2010-05-17 MA MA32842A patent/MA31889B1/fr unknown
-
2011
- 2011-01-12 HK HK11100257.5A patent/HK1146056A1/xx not_active IP Right Cessation
-
2012
- 2012-02-20 HR HR20120166T patent/HRP20120166T1/hr unknown
- 2012-02-23 CY CY20121100185T patent/CY1112391T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
CY1112391T1 (el) | 2015-12-09 |
KR20100082349A (ko) | 2010-07-16 |
ATE534625T1 (de) | 2011-12-15 |
MY148807A (en) | 2013-05-31 |
CA2702933A1 (en) | 2009-04-23 |
RU2478094C2 (ru) | 2013-03-27 |
JP2011500697A (ja) | 2011-01-06 |
EP2215058B1 (en) | 2011-11-23 |
IL205002A0 (en) | 2010-11-30 |
CN101903341A (zh) | 2010-12-01 |
US8222290B2 (en) | 2012-07-17 |
RU2010119554A (ru) | 2011-11-27 |
MA31889B1 (fr) | 2010-12-01 |
CA2702933C (en) | 2012-12-18 |
RS52221B (en) | 2012-10-31 |
PL2215058T3 (pl) | 2012-04-30 |
MX2010003948A (es) | 2010-04-30 |
ZA201002114B (en) | 2010-12-29 |
PT2215058E (pt) | 2012-03-06 |
NZ584692A (en) | 2011-12-22 |
WO2009052068A1 (en) | 2009-04-23 |
SI2215058T1 (sl) | 2012-03-30 |
DK2215058T3 (da) | 2012-03-12 |
US20100173908A1 (en) | 2010-07-08 |
ES2378011T3 (es) | 2012-04-04 |
HK1146056A1 (en) | 2011-05-13 |
AU2008312641A1 (en) | 2009-04-23 |
JP5380455B2 (ja) | 2014-01-08 |
EP2215058A1 (en) | 2010-08-11 |
CN101903341B (zh) | 2012-10-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20120166T1 (hr) | Supstituirane n-bipirolidinuree i njihova upotreba u terapiji | |
RU2436776C2 (ru) | ДИАРИЛАМИН-СОДЕРЖАЩИЕ СОЕДИНЕНИЯ, КОМПОЗИЦИИ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ МОДУЛЯТОРОВ РЕЦЕПТОРОВ с-КIT | |
JP2011500697A5 (pt) | ||
RU2008120850A (ru) | Соединения и композиции в качестве ингибиторов протеинкиназ | |
HRP20090685T1 (hr) | Supstituirani derivati morfolina i tiomorfolina | |
MX2010001080A (es) | Pirrolidin-aril-eteres como antagonistas de receptor de nk3. | |
ME01089B (me) | Derivat benzimidazola i njegova upotreba kao antagonista receptora aii | |
MA31373B1 (fr) | Composes amino-heterocycliques | |
RU2009132189A (ru) | Новые 2-аминооксазолины в качестве лигандов taar1 | |
PE20090160A1 (es) | COMPUESTOS AMINO-5-[4-(DIFLUOROMETOXI)FENIL SUSTITUIDO]-5-FENILIMIDAZOLONA COMO INHIBIDORES DE ß-SECRETASA | |
NZ597498A (en) | Cyclopropyl amine derivatives as histamin H3 receptor modulators | |
HUP0203228A2 (hu) | Szubsztituált indolszármazékok az NFKB-aktivitás módosítására, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
RU2008135690A (ru) | Соединения и композиции в качестве ингибиторов протеинкиназы | |
HRP20110226T1 (hr) | Derivati piperidin-4-il-piridazin-3-ilamina kao brzo disocirajući antagonisti dopamin 2 receptora | |
JP2005527593A5 (pt) | ||
HRP20140687T1 (hr) | Derivati benzofurana | |
RU2008132966A (ru) | Производные циклогексилпиперазинилметанона и их применение в качестве модуляторов гистамин н3 рецептора | |
AR062299A1 (es) | Derivados de bencimidazol | |
HRP20110762T1 (hr) | Supstituirani n-fenilbipirolidinkarboksamidi i njihova upotreba u terapiji | |
HRP20110953T1 (hr) | Supstituirani n-fenilbipirolidinkarboksamidi i njihova upotreba u terapiji | |
NZ617334A (en) | Cyclopropyl amine derivatives | |
HRP20131060T1 (hr) | Derivati fenilpirazola | |
MXPA05010816A (es) | Derivados de 4-(4- (heterociclilalcox}fenil)- 1-(heterociclil- carbonil) piperidina y compuestos relacionados como antagonistas de h3 de la histamina para el tratamiento de enfermedades neurologicas tales como alzheimer. | |
HUP0304101A2 (hu) | Pirazolszármazékok, eljárás előállításukra, alkalmazásuk, a vegyületeket tartalmazó gyógyszerkészítmények és intermedierjeik | |
PE20091431A1 (es) | Compuestos derivados de azetidinas, su preparacion y su aplicacion en terapeutica |